On December 1, 2025 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, reported positive updated interim data for its JANX007, a PSMA-directed TRACTr, Phase 1 clinical program in patients with mCRPC. Janux will host a virtual event on Monday, December 1, 2025, at 4:30 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased JANX007 achieved durable responses with a manageable safety profile that compares favorably to both approved and investigational therapies in mCRPC. Additionally, we found that the ability to transition patients to Q2W dosing may provide meaningful convenience advantages," said David Campbell, Ph.D., President and CEO, Janux Therapeutics. "We look forward to evaluating the potential for JANX007 in earlier-line mCRPC, where improved tolerability and durability could have an even greater impact."

"The early data with JANX007 are highly encouraging. I am deeply committed to this program and inspired by its potential to transform care for mCRPC patients, especially as its potential in earlier-line mCRPC treatment is explored," said Dr. Eleni Efstathiou, Section Chief, Genitourinary Medical Oncology, Houston Methodist Cancer Center and investigator on the trial.

Updated Phase 1 interim clinical data for PSMA-TRACTr JANX007 in mCRPC

As of the October 15, 2025 data cutoff, a total of 109 patients have been treated across the Phase 1a dose escalation and Phase 1b expansion trials of JANX007. The patients enrolled in the Phase 1a trial were heavily pre-treated with a median of four prior lines of therapy. The patients enrolled in the Phase 1b expansion trial were taxane-naïve mCRPC.

Patients from the Phase 1 trials demonstrated high prostate-specific antigen (PSA) response rates and deep PSA declines. Anti-tumor activity was observed with confirmed and unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients.

Encouraging durability was observed in both the QW and every two week (Q2W) expansions with rPFS ranging from 7.9 to 8.9 months and the rPFS of the Q2W expansion group comparing favorably to the QW expansion group.

Preliminary Phase 1b data in taxane-naïve patients demonstrated rapid and deep PSA reductions with primarily grade 1 CRS. Additionally, tumor burden analysis suggests potential for improved rPFS in JANX007 treated earlier line patients.

JANX007 demonstrated a manageable safety profile with cytokine release syndrome (CRS) primarily limited to cycle 1 and grades 1 and 2. Additionally, a CRS mitigation strategy was identified that maintains the grade 1 and 2 CRS profile.

"These findings with JANX007 demonstrate strong efficacy and a CRS safety profile that is predictable and manageable, enabling clinicians to confidently anticipate and address CRS promptly and effectively during early treatment cycles," said Dr. Benjamin Garmezy, Associate Director, Genitourinary Cancer Research; Executive Co-Chair, Genitourinary Cancer Research Executive Committee, Sarah Cannon Research Institute (SCRI) and investigator on the trial.

Janux is advancing JANX007 with a focus on monotherapy and darolutamide combinations in taxane-naïve mCRPC patients. This is the largest and growing mCRPC setting due to increased use of ARPIs in HSPC. Janux also plans to evaluate JANX007 in PARP inhibitor refractory patients as a potential path to an expedited approval.

Webcast Information

Janux will host a live webcast today at 4:30 PM ET. A live analyst question and answer session will follow the formal presentation. To register for the event, please click here.

To access the live webcast, please visit the Investors section of the Company’s website. A replay of the webcast presentation will be available on the Company’s website at View Source for at least 30 days.

Janux’s TRACTr, TRACIr and ARM Pipeline

Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. Janux is also advancing additional CD3-based TRACTr and CD28-based TRACIr programs for future clinical development, including a PSMA-TRACIr for use in combination with our PSMA-TRACTr JANX007, and a TROP2-TRACTr for the treatment of TROP2+ solid tumors. Janux is advancing its first ARM platform program candidate, a CD19-ARM for the potential treatment of autoimmune diseases toward clinical trials. Janux is also generating a number of additional TRACTr, TRACIr and ARM programs for potential future development.

(Press release, Janux Therapeutics, DEC 1, 2025, View Source [SID1234661032])